Refine
Document Type
- Article (7)
- Preprint (4)
- Doctoral Thesis (1)
Has Fulltext
- yes (12)
Is part of the Bibliography
- no (12)
Keywords
- Actin (1)
- Ataxia telangiectasia (1)
- Atm (1)
- Autologous stem cell transplantation (1)
- Dilated cardiomyopathy (1)
- Heart (1)
- High-dose chemotherapy (1)
- Lenalidomide (1)
- Mena/VASP (1)
- Multiple myeloma (1)
Institute
- Physik (7)
- Medizin (3)
- Biochemie und Chemie (1)
- Biowissenschaften (1)
Two-particle correlation functions of negative hadrons over wide phase space, and transverse mass spectra of negative hadrons and deuterons near mid-rapidity have been measured in central Pb+Pb collisions at 158 GeV per nucleon by the NA49 experiment at the CERN SPS. A novel Coulomb correction procedure for the negative two-particle correlations is employed making use of the measured oppositely charged particle correlation. Within an expanding source scenario these results are used to extract the dynamic characteristics of the hadronic source, resolving the ambiguities between the temperature and transverse expansion velocity of the source, that are unavoidable when single and two particle spectra are analysed separately. The source shape, the total duration of the source expansion, the duration of particle emission, the freeze-out temperature and the longitudinal and transverse expansion velocities are deduced.
The directed and elliptic flow of protons and charged pions has been observed from the semi-central collisions of a 158 GeV/nucleon Pb beam with a Pb target. The rapidity and transverse momentum dependence of the flow has been measured. The directed flow of the pions is opposite to that of the protons but both exhibit negative flow at low pt. The elliptic flow of both is fairly independent of rapidity but rises with pt. PACS numbers: 25.75.-q, 25.75.Ld
Using the NA49 main TPC, the central production of hyperons has been measured in CERN SPS Pb - Pb collisions at 158 GeV c-1. The preliminary ratio, studied at 2.0 < y < 2.6 and 1 < pT < 3 GeV c-1, equals ~ (13 ± 4)% (systematic error only). It is compatible, within errors, with the previously obtained ratios for central S + S [1], S + W [2], and S + Au [3] collisions. The fit to the transverse momentum distribution resulted in an inverse slope parameter T of 297 MeV. At this level of statistics we do not see any noticeable enhancement of hyperon production with the increased volume (and, possibly, degree of equilibration) of the system from S + S to Pb + Pb. This result is unexpected and counterintuitive, and should be further investigated. If confirmed, it will have a significant impact on our understanding of mechanisms leading to the enhanced strangeness production in heavy-ion collisions.
Preliminary data on phi production in central Pb + Pb collisions at 158 GeV per nucleon are presented, measured by the NA49 experiment in the hadronic decay channel phi - K+K-. At mid-rapidity, the kaons were separated from pions and protons by combining dE/dx and time-of-flight information; in the forward rapidity range only dE/dx identification was used to obtain the rapidity distribution and a rapidity-integrated mt-spectrum. The mid-rapidity yield obtained was dN/dy = 1.85 ± 0.3 per event; the total phi multiplicity was estimated to be 5.0 ± 0.7 per event. Comparison with published pp data shows a slight, but not very significant strangeness enhancement.
The large acceptance TPCs of the NA49 spectrometer allow for a systematic multidimensional study of two-particle correlations in different part of phase space. Results from Bertsch-Pratt and Yano-Koonin-Podgoretskii parametrizations are presented differentially in transverse pair momentum and pair rapidity. These studies give an insight into the dynamical space-time evolution of relativistic Pb+Pb collisions, which is dominated by longitudinal expansion.
Lambda and Antilambda reconstruction in central Pb+Pb collisions using a time projection chamber
(1997)
The large acceptance time projection chambers of the NA49 experiment are used to record the trajectory of charged particles from Pb + Pb collisions at 158 GeV per nucleon. Neutral strange hadrons have been reconstructed from their charged decay products. To obtain distributions of Λ, and Ks0 in discrete bins of rapidity, y, and transverse momentum, pT, calculations have been performed to determine the acceptance of the detector and the efficiency of the reconstruction software as a function of both variables. The lifetime distributions obtained give values of cτ = 7.8 ± 0.6 cm for Λ and cτ = 2.5 ± 0.3 cm for Ks0, consistent with data book values.
We report measurements of Xi and Xi-bar hyperon absolute yields as a function of rapidity in 158 GeV/c Pb+Pb collisions. At midrapidity, dN/dy = 2.29 +/- 0.12 for Xi, and 0.52 +/- 0.05 for Xi-bar, leading to the ratio of Xi-bar/Xi = 0.23 +/- 0.03. Inverse slope parameters fitted to the measured transverse mass spectra are of the order of 300 MeV near mid-rapidity. The estimated total yield of Xi particles in Pb+Pb central interactions amounts to 7.4 +/- 1.0 per collision. Comparison to Xi production in properly scaled p+p reactions at the same energy reveals a dramatic enhancement (about one order of magnitude) of Xi production in Pb+Pb central collisions over elementary hadron interactions.
Pulmonary failure is the main cause of morbidity and mortality in the human chromosomal instability syndrome Ataxia-telangiectasia (A-T). Major phenotypes include recurrent respiratory tract infections and bronchiectasis, aspiration, respiratory muscle abnormalities, interstitial lung disease, and pulmonary fibrosis. At present, no effective pulmonary therapy for A-T exists. Cell therapy using adipose-derived mesenchymal stromal/stem cells (ASCs) might be a promising approach for tissue regeneration. The aim of the present project was to investigate whether ASCs migrate into the injured lung parenchyma of Atm-deficient mice as an indication of incipient tissue damage during A-T. Therefore, ASCs isolated from luciferase transgenic mice (mASCs) were intravenously transplanted into Atm-deficient and wild-type mice. Retention kinetics of the cells were monitored using in vivo bioluminescence imaging (BLI) and completed by subsequent verification using quantitative real-time polymerase chain reaction (qRT-PCR). The in vivo imaging and the qPCR results demonstrated migration accompanied by a significantly longer retention time of transplanted mASCs in the lung parenchyma of Atm-deficient mice compared to wild type mice. In conclusion, our study suggests incipient damage in the lung parenchyma of Atm-deficient mice. In addition, our data further demonstrate that a combination of luciferase-based PCR together with BLI is a pivotal tool for tracking mASCs after transplantation in models of inflammatory lung diseases such as A-T.
Background: Despite novel therapeutic agents, most multiple myeloma (MM) patients eventually relapse. Two large phase III trials have shown significantly improved response rates (RR) of lenalidomide/dexamethasone compared with placebo/dexamethasone in relapsed MM (RMM) patients. These results have led to the approval of lenalidomide for RMM patients and lenalidomide/dexamethasone has since become a widely accepted second-line treatment. Furthermore, in RMM patients consolidation with high-dose chemotherapy plus autologous stem cell transplantation has been shown to significantly increase progression free survival (PFS) as compared to cyclophosphamide in a phase III trial. The randomized prospective ReLApsE trial is designed to evaluate PFS after lenalidomide/dexamethasone induction, high-dose chemotherapy consolidation plus autologous stem cell transplantation and lenalidomide maintenance compared with the well-established lenalidomide/dexamethasone regimen in RMM patients.
Methods/Design: ReLApsE is a randomized, open, multicenter phase III trial in a planned study population of 282 RMM patients. All patients receive three lenalidomide/dexamethasone cycles and - in absence of available stem cells from earlier harvesting - undergo peripheral blood stem cell mobilization and harvesting. Subsequently, patients in arm A continue on consecutive lenalidomide/dexamethasone cycles, patients in arm B undergo high dose chemotherapy plus autologous stem cell transplantation followed by lenalidomide maintenance until discontinuation criteria are met. Therapeutic response is evaluated after the 3rd (arm A + B) and the 5th lenalidomide/dexamethasone cycle (arm A) or 2 months after autologous stem cell transplantation (arm B) and every 3 months thereafter (arm A + B). After finishing the study treatment, patients are followed up for survival and subsequent myeloma therapies. The expected trial duration is 6.25 years from first patient in to last patient out. The primary endpoint is PFS, secondary endpoints include overall survival (OS), RR, time to best response and the influence of early versus late salvage high dose chemotherapy plus autologous stem cell transplantation on OS.
Discussion: This phase III trial is designed to evaluate whether high dose chemotherapy plus autologous stem cell transplantation and lenalidomide maintenance after lenalidomide/dexamethasone induction improves PFS compared with the well-established continued lenalidomide/dexamethasone regimen in RMM patients. Trial registration: ISRCTN16345835 (date of registration 2010-08-24).
Die Aufklärung der dreidimensionalen Helix-Struktur der DNA, des Trägermoleküls der genetischen Information aller Lebewesen, durch Watson und Crick im Jahre 1953 ermöglichte eine ganz neue Sichtweise auf ihre Eigenschaften und viele zelluläre Prozesse. Von besonderem Interesse sind hier u.a. Mechanismen, bei denen die DNA an den Phosphaten nucleophil substituiert wird, wie dies beispielsweise bei der Rekombination oder der Transkription geschieht. Dies ist daher interessant, weil sich die DNA gegenüber nucleophilen Angriffen in verschiedenen Experimenten als überaus stabil und reaktionsträge gezeigt hat. Spezialisierte Enzyme wie die Staphylokokkennuklease oder Restriktionsendonukleasen nutzen u.a. Metall-Ionen, um Phosphoryltransfer-Reaktionen zu katalysieren und in eine akzeptable Zeitskala zu verschieben. Die Topoisomerase vom Typ I zeigt eindrucksvoll, dass Katalyse solcher Reaktionen auch ohne Metall-Ion möglich ist, womit auch gleichzeitig die Quelle für eine potentielle oxidative Schädigung der DNA entfernt ist. Leider ist die Palette der natürlich vorkommenden Enzyme begrenzt. Die Erforschung und Entwicklung von künstlichen Nukleasen ermöglicht daher potentiell den zukünftigen Einsatz neuer, maßgeschneiderter Werkzeuge für die Biochemie und die Biotechnologie, sowie langfristig die Bereitstellung neuartiger Chemotherapeutika. Vom aktiven Zentrum der Staphylokokkennuklease abgeleitete Moleküle auf Bisguanidinium-Naphthol-Basis bzw. deren Derivate zeigten in der Vergangenheit deutliche Aktivität als metallfreie, unspezifische Spalter von Plasmid-DNA. Die vorliegende Arbeit beschreibt die weitere Entwicklung und Charakterisierung neuer unspezifischer und potentiell sequenzselektiver Bisguanidinium-Naphthol-Derivate. Hierbei wurde eine neue, zuverlässige Synthesestrategie für Bisguanidinium-Naphthole und parallel dazu ein neuer und flexibler Weg der Flüssigphasen-Synthese von DNA-bindenden Polyamiden ausgearbeitet, um daraus DNA-bindende Konjugate herzustellen. Vier unspezifische Moleküle (45, 94, 95, 97) und zwei Konjugate (46 und 140) wurden dann bei physiologischen Bedingungen auf ihre Spaltaktivität gegenüber Plasmid-DNA und linearer Duplex-DNA untersucht. Bei allen oben genannten Verbindungen konnte - verglichen mit der Stamm-Verbindung 36 aus Vorgängerarbeiten - eine erhöhte Aktivität gegenüber Plasmid-DNA bestimmt werden, die im Falle der Konjugate zwischen 4000- und 8000-fach liegt. Zur weiteren Charakterisierung wurden Experimente in Anwesenheit von EDTA oder Mg2+, zur pH-Abhängigkeit und zur Kinetik der Spalt-Reaktion durchgeführt. Erste Testreihen zum Nachweis sequenzselektiver DNA-Spaltung lieferten kein abschließendes Ergebnis, gaben jedoch erste Hinweise auf Selektivität, welche zur Zeit näher untersucht und überprüft werden.